
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Immunol.
Sec. Inflammation
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1518687
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background and aims. Metabolic dysfunction-associated steatohepatitis (MASH) represents a growing cause of liver cirrhosis and hepatocellular carcinoma (HCC). However, effective therapy for MASH is still lacking. Despite recent studies suggest that ketosis might improve MASH evolution, the mechanisms involved have not been explored since common ketogenic diets cause severe steatohepatitis in mice. In this study, we have investigated the capacity of a new-formulated ketogenic diet (KD) containing vegetal fat in improving liver alterations associated with experimental MASH.Methods. MASH was induced in C57BL/6 mice by feeding with a cholesterol-enriched Western Diet (WD) for up to 16 weeks, followed by switching animals to KD for an additional eight weeks.Results. We observed that KD administration greatly increased ketone body production and significantly reduced liver and body weights. Moreover, liver proteomic analysis and functional tests evidenced an improved glucose and lipid metabolism along with insulin resistance in KD-fed mice.These metabolic effects were associated with an amelioration in MASH-associated gut dysbiosis with the recovery of a bacterial flora comparable to that of healthy mice and with an improvement of hepatic steatosis, parenchymal injury and liver fibrosis. From the mechanistic point of view mice receiving KD showed a significant reduction in liver TREM2-positive monocyte-derived macrophages forming crown-like aggregates along with a lowering in the hepatic expression of proinflammatory/pro-fibrogenic markers such as CCL2, IL-12, CD11b, α1-procollagen, TGF-β1, osteopontin, and galectin-3. Consistently, β-hydroxybutyrate supplementation reduced TREM2 and galectin-3 expression by cultured Raw 264.7 macrophages.Conclusions. Altogether, these results indicate that ketogenic diet based on vegetal fat effectively improves MASH metabolic derangements and steatohepatitis, and it might represent a potential therapeutic strategy in this disease.
Keywords: Metabolic dysfunction-associated steatotic liver disease, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis, Liver fibrosis amplicon-sequence variants, α-SMA: α-smooth muscle actin, Gal-3: galectin-3, hCLS: hepatic crown-like structures, KD ketogenic diet, MASH: metabolic dysfunction-associated steatohepatitis, MASLD: metabolic dysfunction-associated steatotic liver disease, NAFLD: nonalcoholic fatty liver disease
Received: 28 Oct 2024; Accepted: 03 Mar 2025.
Copyright: © 2025 Sutti, Provera, Ramavath, Gadipudi, Vecchio, Caputo, Antonioli, Tini, Sheferaw, Reano, Filigheddu, Manfredi, Barberis, Cocolin, Ferrocino, Locatelli, Caprio, Tacke, Albano and Prodam. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Salvatore Sutti, University of Eastern Piedmont, Vercelli, Italy
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.